26.10.2023 16:00:00
|
Lilly to Participate in UBS Biopharma Conference 2023
INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023. Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA; and chief customer officer, will participate in a fireside chat at 3 p.m., Eastern time.
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.
About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news or follow us on Facebook, Instagram and LinkedIn. F-LLY
Refer to: | Jordan Bishop; jordan.bishop@lilly.com; 317-473-5712 (Media) |
Joe Fletcher; jfletcher@lilly.com; 317-296-2884 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-participate-in-ubs-biopharma-conference-2023-301967876.html
SOURCE Eli Lilly and Company
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
17.01.25 |
Börse New York in Grün: S&P 500 nachmittags stärker (finanzen.at) | |
17.01.25 |
Starker Wochentag in New York: S&P 500 klettert mittags (finanzen.at) | |
14.01.25 |
NYSE-Handel: S&P 500 notiert zum Handelsende im Plus (finanzen.at) | |
14.01.25 |
Eli Lilly-Aktie sackt ab: Wachstum 2024 nicht so stark wie erhofft (dpa-AFX) | |
14.01.25 |
Dienstagshandel in New York: S&P 500 am Dienstagnachmittag in der Gewinnzone (finanzen.at) | |
14.01.25 |
S&P 500-Handel aktuell: S&P 500 im Minus (finanzen.at) | |
14.01.25 |
Eli Lilly shares fall after revenue miss for blockbuster weight-loss drugs (Financial Times) | |
14.01.25 |
S&P 500-Papier Eli Lilly-Aktie: So viel Gewinn hätte ein Eli Lilly-Investment von vor 3 Jahren eingefahren (finanzen.at) |
Analysen zu Eli Lillymehr Analysen
20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Eli Lilly | 710,00 | -3,74% |